Effective Reduction of Inflammatory and Coagulation Factors using Sitagliptin in Type 2 Diabetes

IRCMJ logo
PDF
HTML

Keywords

Fibrinogen
hs-CRP
Pioglitazone
Sitagliptin
Type 2 diabetes

How to Cite

GhavamiM., HoushyarJ., MehdizadehA., NajafipourM., & NajafipourF. (2021). Effective Reduction of Inflammatory and Coagulation Factors using Sitagliptin in Type 2 Diabetes . Iranian Red Crescent Medical Journal, 23(3). https://doi.org/10.32592/ircmj.2021.23.3.324

Abstract

Introduction: There are different drug-based treatments (i.e., oral or injective) for patients with type 2 diabetes. Pioglitazone and sitagliptin, among oral agents, can affect blood glucose control and lipid profile.

Objectives: The purpose of the current investigation was the assessment of the effects of adding sitagliptin or pioglitazone (as the third drug) to the combined metformin-sulfonylurea treatment on glycemic control, inflammatory factors, and lipid profile.

Methods: This clinical trial was carried out on 125 patients with type 2 diabetes undergoing metformin-glibenclamide treatment. The patients were randomly divided into three groups, namely the sitagliptin group receiving 100 mg of sitagliptin for 3 months (n=45), pioglitazone group receiving 30 mg of pioglitazone for 3 months (n=40), and control group (n=40). After the interventions, the anthropometric indices, glycated hemoglobin A1c level, lipid profile, fibrinogen, and high-sensitivity C-reactive protein (hs-CRP) were compared among the study groups.

Results: The sitagliptin group demonstrated significantly lower levels of hs-CRP (0.53±0.26 mg/L) and fibrinogen (314.08±48.09 mg/dL), compared to those reported for the pioglitazone and control groups. In contrast, significantly lower triglyceride levels (115.02±32.92 mg/dL) and significantly higher high-density lipoprotein cholesterol (51.57±11.14 mg/dL) were observed in the pioglitazone group in comparison to those reported for the sitagliptin and control groups.

Conclusion: The results of the present study suggest that sitagliptin reduces the levels of fibrinogen and hs-CRP. Nevertheless, pioglitazone has a more significant effect on the improvement of the lipid profile, compared to sitagliptin and combined metformin-sulfonylurea treatments.

 

https://doi.org/10.32592/ircmj.2021.23.3.324
PDF
HTML

References

  1. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133-223. doi: 10.1152/physrev.00063.2017. [PubMed: 30067154].
  2. Samtani MN. Simple pharmacometric tools for oral anti‐diabetic drug development: competitive landscape for oral non‐insulin therapies in type 2 diabetes. Biopharm Drug Dispos. 2010;31(2‐3):162-77. doi: 10.1002/bdd.700. [PubMed: 20213855].
  3. Nanjan M, Mohammed M, Kumar BP, Chandrasekar M. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018;77:548-67. doi: 10.1016/j.bioorg.2018.02.009. [PubMed: 29475164].
  4. Yasmin S, Jayaprakash V. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present. Eur J Med Chem. 2017;126:879-93. doi: 10.1016/j.ejmech.2016.12.020. [PubMed: 27988463].
  5. Al-Azzam SI, AlOmari M, Khader YS, AlMahasneh FA, Muflih SM, Altawalbeh S. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes. Endocr Res. 2012;37(1):7-11. doi: 10.3109/07435800.2011.566238. [PubMed: 21977974].
  6. Filipova E, Uzunova K, Kalinov K, Vekov T. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr. 2017;9(1):90. doi: 10.1186/s13098-017-0290-5. [PubMed: 29163673].
  7. Khaloo P, Komeleh SA, Alemi H, Mansournia M, Mohammadi A, Yadegar A, et al. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea. J Endocrinol Invest. 2019;42(7):851-7. doi: 10.1007/s40618-018-0991-0. [PubMed: 30535871].
  8. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38(2):89-101. doi: 10.1016/j.diabet.2011.11.001. [PubMed: 22197148].
  9. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes. 2010;3:31-41. doi: 10.2147/dmsott.s7327. [PubMed: 21437074].
  10. Derosa G, Ragonesi PD, Fogari E, Cicero AFG, Bianchi L, Bonaventura A, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2‐year study evaluation. Fundam Clin Pharmacol. 2014;28(2):221-9. doi: 10.1111/fcp.12001. [PubMed: 23039403].
  11. Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. 2017;9(7):667-76. doi: 10.1111/1753-0407.12456. [PubMed: 27502307].
  12. Harashima SI, Ogura M, Tanaka D, Fukushima T, Wang Y, Koizumi T, et al. Sitagliptin add‐on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract. 2012;66(5):465-76. doi: 10.1111/j.1742-1241.2012.02903.x. [PubMed: 22512606].
  13. Liu SC, Chien KL, Wang CH, Chen WC, Leung CH. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocr Pract. 2013;19(6):980-8. doi: 10.4158/EP13148.OR. [PubMed: 23807528].
  14. Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013;15(5):455-62. doi: 10.1111/dom.12055. [PubMed: 23279373].
  15. Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A. Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: a randomized controlled trial. J Pharmacol Pharmacother. 2013;4(1):27-32. doi: 10.4103/0976-500X.107656. [PubMed: 23662021].
  16. Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Ann Med. 2016;48(4):224-34. doi: 10.3109/07853890.2016.1157263. [PubMed: 26982210].
  17. Filipova EP, Uzunova KH, Vekov TY. Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins. Diabetol Metab Syndr. 2015;7(1):63. doi: 10.1186/s13098-015-0059-7. [PubMed: 26288659].
  18. Banerjee S. Pioglitazone safe, so safe. J Assoc Physicians India. 2012;60:62-6. [PubMed: 22715548].
  19. Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387-405. doi: 10.1080/14740338.2018.1444027. [PubMed: 29468916].
  20. Jameshorani M, Sayari S, Kiahashemi N, Motamed N. Comparative study on adding pioglitazone or sitagliptin to patients with type 2 diabetes mellitus insufficiently controlled with metformin. Open Access Maced J Med Sci. 2017;5(7):955-62. doi: 10.3889/oamjms.2017.193. [PubMed: 29362626].
  21. Kutoh E. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naive Japanese patients with type 2 diabetes with or without metabolic syndrome. Endocr Res. 2010;35(3):118-27. doi: 10.3109/07435801003762164. [PubMed: 20712426].
  22. Erem C, Ozbas H, Nuhoglu I, Deger O, Civan N, Ersoz H. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2014;122(05):295-302. doi: 10.1055/s-0034-1370989. [PubMed: 24710641].
  23. Fan M, Li Y, Zhang S. Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Medicine. 2016;95(2):e2386. doi: 10.1097/MD.0000000000002386. [PubMed: 26765417].
  24. Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, Najafipour F, Mohamadzadeh Gharebaghi S, Adabi K, et al. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015;6(2):56-60. doi: 10.1177/2042018815574229. [PubMed: 25941563].
  25. Zografou I, Sampanis C, Gkaliagkousi E, Iliadis F, Papageorgiou A, Doukelis P, et al. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. Hormones. 2015;14(1):118-25. doi: 10.14310/horm.2002.1512. [PubMed: 25402372].
  26. Shaheer AK, Tharayil JK, Krishna PW. A comparative study of high sensitivity C-reactive protein and metabolic variables in type 2 diabetes mellitus with and without nephropathy. J Clin Diagn Res. 2017;11(9):BC01-4. doi: 10.7860/JCDR/2017/30272.10528. [PubMed: 29207691].
  27. Umamaheswari A. To compare the anti-inflammatory effect of oral hypoglycemic drugs in type 2 diabetes mellitus. [Masters Thesis]. Coimbatore, India: PSG Institue of Medical Sciences and Research; 2016.
  28. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62(3):347-51. doi: 10.1016/j.metabol.2012.09.004. [PubMed: 23062489].
  29. Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):144. doi: 10.1186/s12944-019-1086-4. [PubMed: 31208420].
  30. Chen R, Yan J, Liu P, Wang Z. Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials. PLoS One. 2015;10(4):e0123703. doi: 10.1371/journal.pone.0123703. [PubMed: 25897968].
  31. Park JS, Cho MH, Nam JS, Yoo JS, Ahn CW, Cha BS, et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2011;164(1):69-74. doi: 10.1530/EJE-10-0875. [PubMed: 20961967].
  32. Kim NH, Kim DL, Kim KJ, Kim NH, Choi KM, Baik SH, et al. Effects of vildagliptin or pioglitazone on glycemic variability and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a 16-week, randomised, open label, pilot study. Endocrinol Metab. 2017;32(2):241-7. doi: 10.3803/EnM.2017.32.2.241. [PubMed: 28685513].
  33. Khan S, Khan S, Panda BP, Akhtar M, Najmi AK. Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. Expert Opin Ther Targets. 2015;19(12):1607-16. doi: 10.1517/14728222.2016.1086338. [PubMed: 26357866].
  34. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925-31. doi: 10.1016/j.jacc.2005.03.041. [PubMed: 15963388].
  35. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69(1):5-13. doi: 10.1016/j.diabres.2004.10.007. [PubMed: 15955382].